aluates Reports

$ 0.0

Automative

Global Malignant Mesothelioma Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-2N14158

Global Malignant Mesothelioma Market Research Report 2023

BUY CHAPTERS

Global Malignant Mesothelioma Market Research Report 2025

Code: QYRE-Auto-2N14158

Report

September 2025

Pages:100

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Malignant Mesothelioma Market Size

The global market for Malignant Mesothelioma was valued at US$ 501 million in the year 2024 and is projected to reach a revised size of US$ 749 million by 2031, growing at a CAGR of 6.0% during the forecast period.

Malignant Mesothelioma Market

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).

Our research indicates that the hospital pharmacies distribution channel segment is expected to witness a significant rise in revenue share over the forecast period, owing to the increasing direct procurement of mesothelioma drugs by governments to ensure availability in hospital pharmacies and oncology centers.

This report aims to provide a comprehensive presentation of the global market for Malignant Mesothelioma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Malignant Mesothelioma.

The Malignant Mesothelioma market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Malignant Mesothelioma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Malignant Mesothelioma companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Malignant Mesothelioma Market Report

Report Metric	Details
Report Name	Malignant Mesothelioma Market
Accounted market size in year	US$ 501 million
Forecasted market size in 2031	US$ 749 million
CAGR	6.0%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Oral Parenteral
Segment by Application	Hospital Pharmacies Retail Pharmacies Oncology Centers Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Corden Pharma, Concordia International, Kyowa Hakko Kirin, Polaris Pharmaceuticals, MolMed, Ono Pharmaceutical, Nichi-Iko Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Malignant Mesothelioma company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Malignant Mesothelioma Market growing?

Ans: The Malignant Mesothelioma Market witnessing a CAGR of 6.0% during the forecast period 2025-2031.

What is the Malignant Mesothelioma Market size in 2031?

Ans: The Malignant Mesothelioma Market size in 2031 will be US$ 749 million.

Who are the main players in the Malignant Mesothelioma Market report?

Ans: The main players in the Malignant Mesothelioma Market are AstraZeneca, Bristol-Myers Squibb, Roche, Merck, Novartis, Pfizer, Sanofi, Eli Lilly, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan, Fresenius Kabi, Sun Pharmaceuticals, Corden Pharma, Concordia International, Kyowa Hakko Kirin, Polaris Pharmaceuticals, MolMed, Ono Pharmaceutical, Nichi-Iko Pharmaceutical

What are the Application segmentation covered in the Malignant Mesothelioma Market report?

Ans: The Applications covered in the Malignant Mesothelioma Market report are Hospital Pharmacies, Retail Pharmacies, Oncology Centers, Others

What are the Type segmentation covered in the Malignant Mesothelioma Market report?

Ans: The Types covered in the Malignant Mesothelioma Market report are Oral, Parenteral

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Malignant Mesothelioma Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Oral

1.2.3 Parenteral

1.3 Market by Application

1.3.1 Global Malignant Mesothelioma Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Oncology Centers

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Malignant Mesothelioma Market Perspective (2020-2031)

2.2 Global Malignant Mesothelioma Growth Trends by Region

2.2.1 Global Malignant Mesothelioma Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Malignant Mesothelioma Historic Market Size by Region (2020-2025)

2.2.3 Malignant Mesothelioma Forecasted Market Size by Region (2026-2031)

2.3 Malignant Mesothelioma Market Dynamics

2.3.1 Malignant Mesothelioma Industry Trends

2.3.2 Malignant Mesothelioma Market Drivers

2.3.3 Malignant Mesothelioma Market Challenges

2.3.4 Malignant Mesothelioma Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Malignant Mesothelioma Players by Revenue

3.1.1 Global Top Malignant Mesothelioma Players by Revenue (2020-2025)

3.1.2 Global Malignant Mesothelioma Revenue Market Share by Players (2020-2025)

3.2 Global Malignant Mesothelioma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Malignant Mesothelioma Revenue

3.4 Global Malignant Mesothelioma Market Concentration Ratio

3.4.1 Global Malignant Mesothelioma Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Revenue in 2024

3.5 Global Key Players of Malignant Mesothelioma Head office and Area Served

3.6 Global Key Players of Malignant Mesothelioma, Product and Application

3.7 Global Key Players of Malignant Mesothelioma, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Malignant Mesothelioma Breakdown Data by Type

4.1 Global Malignant Mesothelioma Historic Market Size by Type (2020-2025)

4.2 Global Malignant Mesothelioma Forecasted Market Size by Type (2026-2031)

5 Malignant Mesothelioma Breakdown Data by Application

5.1 Global Malignant Mesothelioma Historic Market Size by Application (2020-2025)

5.2 Global Malignant Mesothelioma Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Malignant Mesothelioma Market Size (2020-2031)

6.2 North America Malignant Mesothelioma Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Malignant Mesothelioma Market Size by Country (2020-2025)

6.4 North America Malignant Mesothelioma Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Malignant Mesothelioma Market Size (2020-2031)

7.2 Europe Malignant Mesothelioma Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Malignant Mesothelioma Market Size by Country (2020-2025)

7.4 Europe Malignant Mesothelioma Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Malignant Mesothelioma Market Size (2020-2031)

8.2 Asia-Pacific Malignant Mesothelioma Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Malignant Mesothelioma Market Size by Region (2020-2025)

8.4 Asia-Pacific Malignant Mesothelioma Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Malignant Mesothelioma Market Size (2020-2031)

9.2 Latin America Malignant Mesothelioma Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Malignant Mesothelioma Market Size by Country (2020-2025)

9.4 Latin America Malignant Mesothelioma Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Malignant Mesothelioma Market Size (2020-2031)

10.2 Middle East & Africa Malignant Mesothelioma Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Malignant Mesothelioma Market Size by Country (2020-2025)

10.4 Middle East & Africa Malignant Mesothelioma Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 AstraZeneca

11.1.1 AstraZeneca Company Details

11.1.2 AstraZeneca Business Overview

11.1.3 AstraZeneca Malignant Mesothelioma Introduction

11.1.4 AstraZeneca Revenue in Malignant Mesothelioma Business (2020-2025)

11.1.5 AstraZeneca Recent Development

11.2 Bristol-Myers Squibb

11.2.1 Bristol-Myers Squibb Company Details

11.2.2 Bristol-Myers Squibb Business Overview

11.2.3 Bristol-Myers Squibb Malignant Mesothelioma Introduction

11.2.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Business (2020-2025)

11.2.5 Bristol-Myers Squibb Recent Development

11.3 Roche

11.3.1 Roche Company Details

11.3.2 Roche Business Overview

11.3.3 Roche Malignant Mesothelioma Introduction

11.3.4 Roche Revenue in Malignant Mesothelioma Business (2020-2025)

11.3.5 Roche Recent Development

11.4 Merck

11.4.1 Merck Company Details

11.4.2 Merck Business Overview

11.4.3 Merck Malignant Mesothelioma Introduction

11.4.4 Merck Revenue in Malignant Mesothelioma Business (2020-2025)

11.4.5 Merck Recent Development

11.5 Novartis

11.5.1 Novartis Company Details

11.5.2 Novartis Business Overview

11.5.3 Novartis Malignant Mesothelioma Introduction

11.5.4 Novartis Revenue in Malignant Mesothelioma Business (2020-2025)

11.5.5 Novartis Recent Development

11.6 Pfizer

11.6.1 Pfizer Company Details

11.6.2 Pfizer Business Overview

11.6.3 Pfizer Malignant Mesothelioma Introduction

11.6.4 Pfizer Revenue in Malignant Mesothelioma Business (2020-2025)

11.6.5 Pfizer Recent Development

11.7 Sanofi

11.7.1 Sanofi Company Details

11.7.2 Sanofi Business Overview

11.7.3 Sanofi Malignant Mesothelioma Introduction

11.7.4 Sanofi Revenue in Malignant Mesothelioma Business (2020-2025)

11.7.5 Sanofi Recent Development

11.8 Eli Lilly

11.8.1 Eli Lilly Company Details

11.8.2 Eli Lilly Business Overview

11.8.3 Eli Lilly Malignant Mesothelioma Introduction

11.8.4 Eli Lilly Revenue in Malignant Mesothelioma Business (2020-2025)

11.8.5 Eli Lilly Recent Development

11.9 Teva Pharmaceuticals

11.9.1 Teva Pharmaceuticals Company Details

11.9.2 Teva Pharmaceuticals Business Overview

11.9.3 Teva Pharmaceuticals Malignant Mesothelioma Introduction

11.9.4 Teva Pharmaceuticals Revenue in Malignant Mesothelioma Business (2020-2025)

11.9.5 Teva Pharmaceuticals Recent Development

11.10 Boehringer Ingelheim GmbH

11.10.1 Boehringer Ingelheim GmbH Company Details

11.10.2 Boehringer Ingelheim GmbH Business Overview

11.10.3 Boehringer Ingelheim GmbH Malignant Mesothelioma Introduction

11.10.4 Boehringer Ingelheim GmbH Revenue in Malignant Mesothelioma Business (2020-2025)

11.10.5 Boehringer Ingelheim GmbH Recent Development

11.11 Mylan

11.11.1 Mylan Company Details

11.11.2 Mylan Business Overview

11.11.3 Mylan Malignant Mesothelioma Introduction

11.11.4 Mylan Revenue in Malignant Mesothelioma Business (2020-2025)

11.11.5 Mylan Recent Development

11.12 Fresenius Kabi

11.12.1 Fresenius Kabi Company Details

11.12.2 Fresenius Kabi Business Overview

11.12.3 Fresenius Kabi Malignant Mesothelioma Introduction

11.12.4 Fresenius Kabi Revenue in Malignant Mesothelioma Business (2020-2025)

11.12.5 Fresenius Kabi Recent Development

11.13 Sun Pharmaceuticals

11.13.1 Sun Pharmaceuticals Company Details

11.13.2 Sun Pharmaceuticals Business Overview

11.13.3 Sun Pharmaceuticals Malignant Mesothelioma Introduction

11.13.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Business (2020-2025)

11.13.5 Sun Pharmaceuticals Recent Development

11.14 Corden Pharma

11.14.1 Corden Pharma Company Details

11.14.2 Corden Pharma Business Overview

11.14.3 Corden Pharma Malignant Mesothelioma Introduction

11.14.4 Corden Pharma Revenue in Malignant Mesothelioma Business (2020-2025)

11.14.5 Corden Pharma Recent Development

11.15 Concordia International

11.15.1 Concordia International Company Details

11.15.2 Concordia International Business Overview

11.15.3 Concordia International Malignant Mesothelioma Introduction

11.15.4 Concordia International Revenue in Malignant Mesothelioma Business (2020-2025)

11.15.5 Concordia International Recent Development

11.16 Kyowa Hakko Kirin

11.16.1 Kyowa Hakko Kirin Company Details

11.16.2 Kyowa Hakko Kirin Business Overview

11.16.3 Kyowa Hakko Kirin Malignant Mesothelioma Introduction

11.16.4 Kyowa Hakko Kirin Revenue in Malignant Mesothelioma Business (2020-2025)

11.16.5 Kyowa Hakko Kirin Recent Development

11.17 Polaris Pharmaceuticals

11.17.1 Polaris Pharmaceuticals Company Details

11.17.2 Polaris Pharmaceuticals Business Overview

11.17.3 Polaris Pharmaceuticals Malignant Mesothelioma Introduction

11.17.4 Polaris Pharmaceuticals Revenue in Malignant Mesothelioma Business (2020-2025)

11.17.5 Polaris Pharmaceuticals Recent Development

11.18 MolMed

11.18.1 MolMed Company Details

11.18.2 MolMed Business Overview

11.18.3 MolMed Malignant Mesothelioma Introduction

11.18.4 MolMed Revenue in Malignant Mesothelioma Business (2020-2025)

11.18.5 MolMed Recent Development

11.19 Ono Pharmaceutical

11.19.1 Ono Pharmaceutical Company Details

11.19.2 Ono Pharmaceutical Business Overview

11.19.3 Ono Pharmaceutical Malignant Mesothelioma Introduction

11.19.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Business (2020-2025)

11.19.5 Ono Pharmaceutical Recent Development

11.20 Nichi-Iko Pharmaceutical

11.20.1 Nichi-Iko Pharmaceutical Company Details

11.20.2 Nichi-Iko Pharmaceutical Business Overview

11.20.3 Nichi-Iko Pharmaceutical Malignant Mesothelioma Introduction

11.20.4 Nichi-Iko Pharmaceutical Revenue in Malignant Mesothelioma Business (2020-2025)

11.20.5 Nichi-Iko Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

List of Tables

Table 1. Global Malignant Mesothelioma Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Oral

Table 3. Key Players of Parenteral

Table 4. Global Malignant Mesothelioma Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Malignant Mesothelioma Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Malignant Mesothelioma Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Malignant Mesothelioma Market Share by Region (2020-2025)

Table 8. Global Malignant Mesothelioma Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Malignant Mesothelioma Market Share by Region (2026-2031)

Table 10. Malignant Mesothelioma Market Trends

Table 11. Malignant Mesothelioma Market Drivers

Table 12. Malignant Mesothelioma Market Challenges

Table 13. Malignant Mesothelioma Market Restraints

Table 14. Global Malignant Mesothelioma Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Malignant Mesothelioma Market Share by Players (2020-2025)

Table 16. Global Top Malignant Mesothelioma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma as of 2024)

Table 17. Ranking of Global Top Malignant Mesothelioma Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Malignant Mesothelioma Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Malignant Mesothelioma, Headquarters and Area Served

Table 20. Global Key Players of Malignant Mesothelioma, Product and Application

Table 21. Global Key Players of Malignant Mesothelioma, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Malignant Mesothelioma Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Malignant Mesothelioma Revenue Market Share by Type (2020-2025)

Table 25. Global Malignant Mesothelioma Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Malignant Mesothelioma Revenue Market Share by Type (2026-2031)

Table 27. Global Malignant Mesothelioma Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Malignant Mesothelioma Revenue Market Share by Application (2020-2025)

Table 29. Global Malignant Mesothelioma Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Malignant Mesothelioma Revenue Market Share by Application (2026-2031)

Table 31. North America Malignant Mesothelioma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Malignant Mesothelioma Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Malignant Mesothelioma Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Malignant Mesothelioma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Malignant Mesothelioma Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Malignant Mesothelioma Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Malignant Mesothelioma Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Malignant Mesothelioma Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Malignant Mesothelioma Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Malignant Mesothelioma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Malignant Mesothelioma Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Malignant Mesothelioma Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Malignant Mesothelioma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Malignant Mesothelioma Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Malignant Mesothelioma Market Size by Country (2026-2031) & (US$ Million)

Table 46. AstraZeneca Company Details

Table 47. AstraZeneca Business Overview

Table 48. AstraZeneca Malignant Mesothelioma Product

Table 49. AstraZeneca Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 50. AstraZeneca Recent Development

Table 51. Bristol-Myers Squibb Company Details

Table 52. Bristol-Myers Squibb Business Overview

Table 53. Bristol-Myers Squibb Malignant Mesothelioma Product

Table 54. Bristol-Myers Squibb Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 55. Bristol-Myers Squibb Recent Development

Table 56. Roche Company Details

Table 57. Roche Business Overview

Table 58. Roche Malignant Mesothelioma Product

Table 59. Roche Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 60. Roche Recent Development

Table 61. Merck Company Details

Table 62. Merck Business Overview

Table 63. Merck Malignant Mesothelioma Product

Table 64. Merck Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 65. Merck Recent Development

Table 66. Novartis Company Details

Table 67. Novartis Business Overview

Table 68. Novartis Malignant Mesothelioma Product

Table 69. Novartis Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 70. Novartis Recent Development

Table 71. Pfizer Company Details

Table 72. Pfizer Business Overview

Table 73. Pfizer Malignant Mesothelioma Product

Table 74. Pfizer Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 75. Pfizer Recent Development

Table 76. Sanofi Company Details

Table 77. Sanofi Business Overview

Table 78. Sanofi Malignant Mesothelioma Product

Table 79. Sanofi Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 80. Sanofi Recent Development

Table 81. Eli Lilly Company Details

Table 82. Eli Lilly Business Overview

Table 83. Eli Lilly Malignant Mesothelioma Product

Table 84. Eli Lilly Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 85. Eli Lilly Recent Development

Table 86. Teva Pharmaceuticals Company Details

Table 87. Teva Pharmaceuticals Business Overview

Table 88. Teva Pharmaceuticals Malignant Mesothelioma Product

Table 89. Teva Pharmaceuticals Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 90. Teva Pharmaceuticals Recent Development

Table 91. Boehringer Ingelheim GmbH Company Details

Table 92. Boehringer Ingelheim GmbH Business Overview

Table 93. Boehringer Ingelheim GmbH Malignant Mesothelioma Product

Table 94. Boehringer Ingelheim GmbH Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 95. Boehringer Ingelheim GmbH Recent Development

Table 96. Mylan Company Details

Table 97. Mylan Business Overview

Table 98. Mylan Malignant Mesothelioma Product

Table 99. Mylan Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 100. Mylan Recent Development

Table 101. Fresenius Kabi Company Details

Table 102. Fresenius Kabi Business Overview

Table 103. Fresenius Kabi Malignant Mesothelioma Product

Table 104. Fresenius Kabi Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 105. Fresenius Kabi Recent Development

Table 106. Sun Pharmaceuticals Company Details

Table 107. Sun Pharmaceuticals Business Overview

Table 108. Sun Pharmaceuticals Malignant Mesothelioma Product

Table 109. Sun Pharmaceuticals Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 110. Sun Pharmaceuticals Recent Development

Table 111. Corden Pharma Company Details

Table 112. Corden Pharma Business Overview

Table 113. Corden Pharma Malignant Mesothelioma Product

Table 114. Corden Pharma Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 115. Corden Pharma Recent Development

Table 116. Concordia International Company Details

Table 117. Concordia International Business Overview

Table 118. Concordia International Malignant Mesothelioma Product

Table 119. Concordia International Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 120. Concordia International Recent Development

Table 121. Kyowa Hakko Kirin Company Details

Table 122. Kyowa Hakko Kirin Business Overview

Table 123. Kyowa Hakko Kirin Malignant Mesothelioma Product

Table 124. Kyowa Hakko Kirin Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 125. Kyowa Hakko Kirin Recent Development

Table 126. Polaris Pharmaceuticals Company Details

Table 127. Polaris Pharmaceuticals Business Overview

Table 128. Polaris Pharmaceuticals Malignant Mesothelioma Product

Table 129. Polaris Pharmaceuticals Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 130. Polaris Pharmaceuticals Recent Development

Table 131. MolMed Company Details

Table 132. MolMed Business Overview

Table 133. MolMed Malignant Mesothelioma Product

Table 134. MolMed Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 135. MolMed Recent Development

Table 136. Ono Pharmaceutical Company Details

Table 137. Ono Pharmaceutical Business Overview

Table 138. Ono Pharmaceutical Malignant Mesothelioma Product

Table 139. Ono Pharmaceutical Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 140. Ono Pharmaceutical Recent Development

Table 141. Nichi-Iko Pharmaceutical Company Details

Table 142. Nichi-Iko Pharmaceutical Business Overview

Table 143. Nichi-Iko Pharmaceutical Malignant Mesothelioma Product

Table 144. Nichi-Iko Pharmaceutical Revenue in Malignant Mesothelioma Business (2020-2025) & (US$ Million)

Table 145. Nichi-Iko Pharmaceutical Recent Development

Table 146. Research Programs/Design for This Report

Table 147. Key Data Information from Secondary Sources

Table 148. Key Data Information from Primary Sources

Table 149. Authors List of This Report

List of Figures

Figure 1. Malignant Mesothelioma Picture

Figure 2. Global Malignant Mesothelioma Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Malignant Mesothelioma Market Share by Type: 2024 VS 2031

Figure 4. Oral Features

Figure 5. Parenteral Features

Figure 6. Global Malignant Mesothelioma Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Malignant Mesothelioma Market Share by Application: 2024 VS 2031

Figure 8. Hospital Pharmacies Case Studies

Figure 9. Retail Pharmacies Case Studies

Figure 10. Oncology Centers Case Studies

Figure 11. Others Case Studies

Figure 12. Malignant Mesothelioma Report Years Considered

Figure 13. Global Malignant Mesothelioma Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Malignant Mesothelioma Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Malignant Mesothelioma Market Share by Region: 2024 VS 2031

Figure 16. Global Malignant Mesothelioma Market Share by Players in 2024

Figure 17. Global Top Malignant Mesothelioma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Malignant Mesothelioma as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Malignant Mesothelioma Revenue in 2024

Figure 19. North America Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Malignant Mesothelioma Market Share by Country (2020-2031)

Figure 21. United States Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Malignant Mesothelioma Market Share by Country (2020-2031)

Figure 25. Germany Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Malignant Mesothelioma Market Share by Region (2020-2031)

Figure 33. China Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Malignant Mesothelioma Market Share by Country (2020-2031)

Figure 41. Mexico Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Malignant Mesothelioma Market Share by Country (2020-2031)

Figure 45. Turkey Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Malignant Mesothelioma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. AstraZeneca Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 50. Roche Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 51. Merck Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 52. Novartis Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 53. Pfizer Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 54. Sanofi Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 55. Eli Lilly Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 56. Teva Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 57. Boehringer Ingelheim GmbH Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 58. Mylan Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 59. Fresenius Kabi Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 60. Sun Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 61. Corden Pharma Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 62. Concordia International Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 63. Kyowa Hakko Kirin Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 64. Polaris Pharmaceuticals Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 65. MolMed Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 66. Ono Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 67. Nichi-Iko Pharmaceutical Revenue Growth Rate in Malignant Mesothelioma Business (2020-2025)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-9U20281

Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global AI Contouring Software for Radiotherapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32T20006

Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Cell Senescence β-Galactosidase Staining Kit Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-0Q20500

Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Global Kinase Inhibitors For Cancer Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-18V16958

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Malignant Mesothelioma Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-2N14158

Global Malignant Mesothelioma Market Research Report 2025

FEATURED COMPANIES

Malignant Mesothelioma Market Size

Malignant Mesothelioma Market

Scope of Malignant Mesothelioma Market Report

Chapter Outline

FAQ for this report

How fast is Malignant Mesothelioma Market growing?

What is the Malignant Mesothelioma Market size in 2031?

Who are the main players in the Malignant Mesothelioma Market report?

What are the Application segmentation covered in the Malignant Mesothelioma Market report?

What are the Type segmentation covered in the Malignant Mesothelioma Market report?

FEATURED COMPANIES

RELATED REPORTS